BrainStorm Cell Therapeutics Inc. (BCLI) stock
BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
BrainStorm Cell Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
BrainStorm Cell Therapeutics's free cash flow for the twelve months ending Dec 31, 2023 was -$20.48M. For fiscal 2023 it was -$20.48M. The highest annual figure on record is -$2.07M in fiscal 2010.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$20.48M | – |
| FY2022 | Dec 31, 2022 | -$19.35M | – |
| FY2021 | Dec 31, 2021 | -$26.60M | – |
| FY2020 | Dec 31, 2020 | -$35.57M | – |
| FY2019 | Dec 31, 2019 | -$11.72M | – |
| FY2018 | Dec 31, 2018 | -$12.76M | – |
| FY2017 | Dec 31, 2017 | -$2.54M | – |
| FY2016 | Dec 31, 2016 | -$5.96M | – |
| FY2015 | Dec 31, 2015 | -$7.45M | – |
| FY2014 | Dec 31, 2014 | -$4.65M | – |
| FY2013 | Dec 31, 2013 | -$4.16M | – |
| FY2012 | Dec 31, 2012 | -$3.03M | – |
| FY2011 | Dec 31, 2011 | -$2.27M | – |
| FY2010 | Dec 31, 2010 | -$2.07M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$3.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.43M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.65M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.15M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.70M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.70M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.36M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.00M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.81M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.71M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.04M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.62M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.73M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.53M | – |
| Q1 FY2019 | Mar 31, 2019 | -$839.00K | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.83M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.60M | -275.5% |
| Q2 FY2018 | Jun 30, 2018 | -$160.00K | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.17M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.00M | – |
| Q3 FY2017 | Sep 30, 2017 | $3.76M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.66M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.64M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.20M | – |
| Q3 FY2016 | Sep 30, 2016 | -$286.00K | – |
See a number that looks wrong?